BeOne shows liver and lung cancer data at ESMO 2026
BeOne Medicines presented new data at the ESMO 2026 congress on drugs for liver, lung and breast cancers, including the Phase 3 KANDELA-302 trial.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
BeOne Medicines has released new results for its solid tumor drugs at the European Society for Medical Oncology congress, ESMO 2026, held in Madrid from October 23 to 27. The presentations cover gastrointestinal, lung and breast cancers.
The most notable data concern the bispecific antibody BGB-B2033 in hepatocellular carcinoma. The company reports a confirmed objective response rate of 36.0% at the recommended Phase 3 dose. It also said the global Phase 3 KANDELA-302 study of its CDK4 inhibitor BGB-43395 in first-line breast cancer has begun enrolling.
BeOne plans to start registrational trials of BGB-B2033 in late-line liver cancer by the end of 2026.
why it matters
For investors this is mainly news for the biotech and oncology sector. Early trial results matter for assessing the prospects of individual drugs but do not produce a quick effect on the broader market.
tags
instruments
sources
- BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026 — TradingView, 24 October 2026 at 08:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗